David A Drew1, Daniel E Weiner2, Hocine Tighiouart3, Sarah Duncan2, Aditi Gupta4, Tammy Scott5, Mark J Sarnak2. 1. Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA. Electronic address: ddrew@tuftsmedicalcenter.org. 2. Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA. 3. Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA; Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA. 4. Division of Nephrology and Hypertension, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS. 5. Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA.
Abstract
BACKGROUND: Cognitive impairment is common in patients treated with hemodialysis. The trajectory of cognitive function and risk factors for cognitive decline remain uncertain in this population. STUDY DESIGN: Longitudinal cohort. SETTING & PARTICIPANTS: 314 prevalent hemodialysis patients. PREDICTORS: Age, sex, race, education level, hemodialysis vintage, cause of end-stage renal disease, and baseline history of cardiovascular disease. OUTCOMES: Cognitive function as determined by a comprehensive neurocognitive battery, administered at baseline and yearly when possible. Individual cognitive test results were reduced into 2 domain scores using principal components analysis, representing memory and executive function, which were used as our coprimary outcomes and by definition have a mean of zero and SD of 1. RESULTS: Mean age was 63 years; 54% were men, 22% were black, and 90% had at least a high school education. During a median follow-up of 2.1 (IQR, 0.9-4.2) years, 196 had at least 1 follow-up test, 156 died, and 43 received a kidney transplant. Linear mixed models and joint models, which accounted for competing risks from death, dropout, or kidney transplantation, showed nearly identical results. The joint model demonstrated a decline in executive function (-0.09 [95% CI, -0.13 to -0.05] SD per year), whereas memory improved slightly (0.05 [95% CI, 0.02 to 0.08] SD per year). A significant yearly decline was also seen in the Mini-Mental State Examination score (median change, -0.41; 95% CI, -0.57 to -0.25). Older age was the only significant risk factor for steeper executive function decline (-0.04 [95% CI, -0.06 to -0.02] SD steeper annual decline for each 10 years of age). LIMITATIONS: Prevalent hemodialysis patients only, limited follow-up testing due to high mortality rate, and exclusion of participants with severe cognitive deficits or dementia. CONCLUSIONS: Prevalent hemodialysis patients demonstrate significant cognitive decline, particularly within tests of executive function. Older age was the only statistically significant risk factor for steeper cognitive decline, which may have important clinical consequences for patient management and education. Future studies should evaluate strategies to maintain or improve cognitive function.
BACKGROUND:Cognitive impairment is common in patients treated with hemodialysis. The trajectory of cognitive function and risk factors for cognitive decline remain uncertain in this population. STUDY DESIGN: Longitudinal cohort. SETTING & PARTICIPANTS: 314 prevalent hemodialysis patients. PREDICTORS: Age, sex, race, education level, hemodialysis vintage, cause of end-stage renal disease, and baseline history of cardiovascular disease. OUTCOMES: Cognitive function as determined by a comprehensive neurocognitive battery, administered at baseline and yearly when possible. Individual cognitive test results were reduced into 2 domain scores using principal components analysis, representing memory and executive function, which were used as our coprimary outcomes and by definition have a mean of zero and SD of 1. RESULTS: Mean age was 63 years; 54% were men, 22% were black, and 90% had at least a high school education. During a median follow-up of 2.1 (IQR, 0.9-4.2) years, 196 had at least 1 follow-up test, 156 died, and 43 received a kidney transplant. Linear mixed models and joint models, which accounted for competing risks from death, dropout, or kidney transplantation, showed nearly identical results. The joint model demonstrated a decline in executive function (-0.09 [95% CI, -0.13 to -0.05] SD per year), whereas memory improved slightly (0.05 [95% CI, 0.02 to 0.08] SD per year). A significant yearly decline was also seen in the Mini-Mental State Examination score (median change, -0.41; 95% CI, -0.57 to -0.25). Older age was the only significant risk factor for steeper executive function decline (-0.04 [95% CI, -0.06 to -0.02] SD steeper annual decline for each 10 years of age). LIMITATIONS: Prevalent hemodialysis patients only, limited follow-up testing due to high mortality rate, and exclusion of participants with severe cognitive deficits or dementia. CONCLUSIONS: Prevalent hemodialysis patients demonstrate significant cognitive decline, particularly within tests of executive function. Older age was the only statistically significant risk factor for steeper cognitive decline, which may have important clinical consequences for patient management and education. Future studies should evaluate strategies to maintain or improve cognitive function.
Authors: Emma O'Lone; Michael Connors; Philip Masson; Sunny Wu; Patrick J Kelly; David Gillespie; Daniel Parker; William Whiteley; Giovanni F M Strippoli; Suetonia C Palmer; Jonathan C Craig; Angela C Webster Journal: Am J Kidney Dis Date: 2016-02-23 Impact factor: 8.860
Authors: Mark J Sarnak; Hocine Tighiouart; Tammy M Scott; Kristina V Lou; Eric P Sorensen; Lena M Giang; David A Drew; Kamran Shaffi; James A Strom; Ajay K Singh; Daniel E Weiner Journal: Neurology Date: 2013-01-09 Impact factor: 9.910
Authors: Sarah E Vermeer; Niels D Prins; Tom den Heijer; Albert Hofman; Peter J Koudstaal; Monique M B Breteler Journal: N Engl J Med Date: 2003-03-27 Impact factor: 91.245
Authors: Stephen L Seliger; Daniel L Gillen; W T Longstreth; Bryan Kestenbaum; Catherine O Stehman-Breen Journal: Kidney Int Date: 2003-08 Impact factor: 10.612
Authors: Mara A McAdams-DeMarco; Jingwen Tan; Megan L Salter; Alden Gross; Lucy A Meoni; Bernard G Jaar; Wen-Hong Linda Kao; Rulan S Parekh; Dorry L Segev; Stephen M Sozio Journal: Clin J Am Soc Nephrol Date: 2015-11-16 Impact factor: 8.237
Authors: Mara A McAdams-DeMarco; Matthew Daubresse; Sunjae Bae; Alden L Gross; Michelle C Carlson; Dorry L Segev Journal: Clin J Am Soc Nephrol Date: 2018-08-09 Impact factor: 8.237
Authors: Harmke A Polinder-Bos; David Vállez García; Johanna Kuipers; Jan Willem J Elting; Marcel J H Aries; Wim P Krijnen; Henk Groen; Antoon T M Willemsen; Peter J van Laar; Fijanne Strijkert; Gert Luurtsema; Riemer H J A Slart; Ralf Westerhuis; Ron T Gansevoort; Carlo A J M Gaillard; Casper F M Franssen Journal: J Am Soc Nephrol Date: 2018-03-01 Impact factor: 10.121
Authors: Anoop Sheshadri; Piyawan Kittiskulnam; Cynthia Delgado; Rebecca L Sudore; Jennifer C Lai; Kirsten L Johansen Journal: Am J Nephrol Date: 2021-05-12 Impact factor: 3.754
Authors: Diana Maria Ariton; Joan Jiménez-Balado; Olga Maisterra; Francesc Pujadas; María José Soler; Pilar Delgado Journal: J Clin Med Date: 2021-05-27 Impact factor: 4.241